Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.56 |
| ▸ | NPY4R | P50391 | 4/20 | 0.54 |
| ▸ | NPY1R | P25929 | 3/20 | 0.54 |
| ▸ | NPY2R | P49146 | 3/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402619 | 0.84 | OPRM1 (0.58) | NMUR2NMUR1NPY1ROPRM1OPRK1 | |
| SCHEMBL13402428 | 0.84 | OPRM1 (0.58) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL29629297 | 0.84 | EPHA2 (0.51) | NMUR2NMUR1OPRM1EPHA2NTSR2 | |
| SCHEMBL13402670 | 0.84 | OPRM1 (0.62) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL30680640 | 0.83 | NMUR2 (0.61) | NMUR2NMUR1NPY1RKDM1AEPHA2 | |
| SCHEMBL29657984 | 0.83 | EPHA2 (0.57) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL30943511 | 0.83 | NMUR2 (0.58) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL30436277 | 0.83 | NTSR1 (0.60) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL31239093 | 0.83 | NMUR2 (0.58) | NMUR2NMUR1NPY4RNPY1RNPY2R | |
| SCHEMBL31575684 | 0.83 | KDM1A (0.56) | NPY4RNPY1RNPY2RNPY5RKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242586-A1 | RAS INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242586-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | NMUR2 3532/4885NMUR1 3474/4885NPY4R 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.